Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol-remifentanil vs propofol-dexmedetomidine for pain after awake craniotomy
IRCT20151221025641N5Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of propofol, remifentanil and dexmedetomidine in brain neoplasm (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: postoperative pain intensity. Started Apr 2023; status: completed.
02
Drugs
propofolremifentanildexmedetomidine
03
Conditions
brain neoplasm
Beyond the preview
Go deeper on IRCT20151221025641N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151221025641N5.